It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A comprehensive investigation of ovarian cancer (OC) progression at the single-cell level is crucial for enhancing our understanding of the disease, as well as for the development of better diagnoses and treatments. Here, over half a million single-cell transcriptome data were collected from 84 OC patients across all clinical stages. Through integrative analysis, we identified heterogeneous epithelial-immune-stromal cellular compartments and their interactions in the OC microenvironment. The epithelial cells displayed clinical subtype features with functional variance. A significant increase in distinct T cell subtypes was identified including Tregs and CD8+ exhausted T cells from stage IC2. Additionally, we discovered antigen-presenting cancer-associated fibroblasts (CAFs), with myofibroblastic CAFs (myCAFs) exhibiting enriched extracellular matrix (ECM) functionality linked to tumor progression at stage IC2. Furthermore, the NECTIN2-TIGIT ligand-receptor pair was identified to mediate T cells communicating with epithelial, fibroblast, endothelial, and other cell types. Knock-out of NECTIN2 using CRISPR/Cas9 inhibited ovarian cancer cell (SKOV3) proliferation, and increased T cell proliferation when co-cultured. These findings shed light on the cellular compartments and functional aspects of OC, providing insights into the molecular mechanisms underlying stage IC2 and potential therapeutic strategies for OC.
A single-cell interaction study on ovarian cancer reveals heterogeneous epithelial-immune-stromal cellular compartments and their interactions in shaping the tumor microenvironment, especially through the NECTIN2-TIGIT interaction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Chinese Academy of Sciences, College of Life Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeScience, BGI Research, Qingdao, China (GRID:grid.410726.6); BGI Research, Shenzhen, China (GRID:grid.410726.6)
2 Aarhus University, Department of Biomedicine, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
3 Huazhong University of Science and Technology, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Wuhan, China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223)
4 University of Chinese Academy of Sciences, College of Life Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeScience, BGI Research, Qingdao, China (GRID:grid.410726.6)
5 Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeScience, BGI Research, Qingdao, China (GRID:grid.7048.b); BGI Research, Shenzhen, China (GRID:grid.7048.b)
6 Aarhus University, Department of Biomedicine, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722); Aarhus University Hospital, Steno Diabetes Center Aarhus, Aarhus, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X)
7 Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeScience, BGI Research, Qingdao, China (GRID:grid.154185.c); BGI Research, Shenzhen, China (GRID:grid.154185.c); Aarhus University, Department of Biomedicine, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
8 Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeScience, BGI Research, Qingdao, China (GRID:grid.7048.b); BGI Research, Shenzhen, China (GRID:grid.7048.b); Aarhus University, Department of Biomedicine, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722); Aarhus University Hospital, Steno Diabetes Center Aarhus, Aarhus, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X)